Literature DB >> 25446732

IBS: biomarkers for IBS: ready for prime time?

Giovanni Barbara1.   

Abstract

Evidence is mounting that molecular mechanisms underlie gut dysfunction and symptom generation in IBS. Although it is still an uphill struggle, this mounting evidence is a good starting point for the discovery of one or more IBS biomarkers.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25446732     DOI： 10.1038/nrgastro.2014.217

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads.

Authors:  M P Jones; W D Chey; S Singh; H Gong; R Shringarpure; N Hoe; E Chuang; N J Talley
Journal:  Aliment Pharmacol Ther       Date:  2014-01-06       Impact factor: 8.171

Review 3.  Biomarkers in IBS: when will they replace symptoms for diagnosis and management?

Authors:  Giovanni Barbara; Vincenzo Stanghellini
Journal:  Gut       Date:  2009-12       Impact factor: 23.059

Review 4.  Peripheral mechanisms in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

5.  An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.

Authors:  Ian B Jeffery; Paul W O'Toole; Lena Öhman; Marcus J Claesson; Jennifer Deane; Eamonn M M Quigley; Magnus Simrén
Journal:  Gut       Date:  2011-12-16       Impact factor: 23.059

6.  Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.

Authors:  Mirjana Rajilić-Stojanović; Elena Biagi; Hans G H J Heilig; Kajsa Kajander; Riina A Kekkonen; Sebastian Tims; Willem M de Vos
Journal:  Gastroenterology       Date:  2011-08-05       Impact factor: 22.682

7.  Burden of gastrointestinal disease in the United States: 2012 update.

Authors:  Anne F Peery; Evan S Dellon; Jennifer Lund; Seth D Crockett; Christopher E McGowan; William J Bulsiewicz; Lisa M Gangarosa; Michelle T Thiny; Karyn Stizenberg; Douglas R Morgan; Yehuda Ringel; Hannah P Kim; Marco Dacosta DiBonaventura; Charlotte F Carroll; Jeffery K Allen; Suzanne F Cook; Robert S Sandler; Michael D Kappelman; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2012-08-08       Impact factor: 22.682

8.  Use of serum biomarkers in a diagnostic test for irritable bowel syndrome.

Authors:  A J Lembo; B Neri; J Tolley; D Barken; S Carroll; H Pan
Journal:  Aliment Pharmacol Ther       Date:  2009-04-15       Impact factor: 8.171

9.  Validating biomarkers of treatable mechanisms in irritable bowel syndrome.

Authors:  M Camilleri; A Shin; I Busciglio; P Carlson; A Acosta; A E Bharucha; D Burton; J Lamsam; A Lueke; L J Donato; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2014-09-22       Impact factor: 3.598

10.  Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

Authors:  Giovanni Barbara; Vincenzo Stanghellini; Roberto De Giorgio; Cesare Cremon; Graeme S Cottrell; Donatella Santini; Gianandrea Pasquinelli; Antonio M Morselli-Labate; Eileen F Grady; Nigel W Bunnett; Stephen M Collins; Roberto Corinaldesi
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682
  10 in total
  4 in total

1.  Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome.

Authors:  Hannah Ceuleers; Nikita Hanning; Jelena Heirbaut; Samuel Van Remoortel; Jurgen Joossens; Pieter Van Der Veken; Sven M Francque; Michelle De Bruyn; Anne-Marie Lambeir; Joris G De Man; Jean-Pierre Timmermans; Koen Augustyns; Ingrid De Meester; Benedicte Y De Winter
Journal:  Br J Pharmacol       Date:  2018-07-23       Impact factor: 8.739

Review 2.  Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders.

Authors:  M Camilleri
Journal:  Aliment Pharmacol Ther       Date:  2015-08-11       Impact factor: 8.171

Review 3.  Recent advances in understanding non-celiac gluten sensitivity.

Authors:  Maria Raffaella Barbaro; Cesare Cremon; Vincenzo Stanghellini; Giovanni Barbara
Journal:  F1000Res       Date:  2018-10-11

Review 4.  Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome.

Authors:  Yoshiyuki Mishima; Shunji Ishihara
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.